ArticlePLoS neglected tropical diseases2025
Chikungunya virus seroprevalence among febrile patients in selected health facilities in Mount Elgon region, Kenya.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChikungunya is an emerging vector-borne disease of global significance, known for causing acute illness characterized by fever and severe arthralgia, which can evolve to chronic arthritis and rheumatism especially in elderly patients. While febrile illness and arthralgia are common clinical presentations among residents of Mount Elgon (Mt. Elgon), the role of chikungunya virus as a causative agent is undocumented. This study aimed to assess the prevalence of antibodies against Chikungunya Virus (CHIKV) antigens in patients presenting with acute febrile illnesses (AFI) in Mt. Elgon region, Kenya.
methodsThis cross-sectional seroprevalence study involved febrile patients visiting selected health facilities in the region. Serum samples were collected and screened for 1gG + IgM + IgA antibodies using an indirect Enzyme Linked Immunosorbent Assay (ELISA). Positive samples were further analyzed using standard plaque reduction neutralization assay (PRNT) on Vero (Biken) E6 cell cultures for confirmation of presence of neutralizing antibodies against CHIKV.
resultsELISA results indicated that 317/1359 (23.33%) serum samples were positive for CHIKV antibodies. Of these, 305 samples (96.21%) were subjected to PRNT, 127 samples (9.3%) tested positive for CHIKV neutralizing antibodies.
conclusionThese findings indicate active circulation of CHIKV in Mt. Elgon region. This underscores the need for enhanced surveillance and monitoring strategies to mitigate the risk of potential outbreaks in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.